WebIrinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies Article Mar 2024 David Bing Zhen Rachel L McDevitt... WebJun 28, 2024 · Irinotecan-induced dysarthria has been reported in the literature, but the underlying mechanism of this neurotoxicity remains unclear. Here, we present a 35-year-old female with metastatic colon ...
Recurrent Transient Dysarthria Due to FOLFIRINOX
WebMar 21, 2024 · Irinotecan (Camptosar ©, CPT-11), a topoisomerase I inhibitor, is a commonly used cytotoxic chemotherapeutic in the treatment of multiple malignancies, … WebJan 19, 2013 · Irinotecan. A 34-year-old man with metastatic sarcoma and a 63-year-old woman with disseminated adenocarcinoma developed CNS toxicity with dysarthria during treatment with irinotecan. The woman also experienced an acute cholinergic syndrome. The man, who had experienced partial remission of his sarcoma following antineoplastic … diablo 2 the seven tombs
(PDF) Irinotecan-Associated Dysarthria in Patients with Pancreatic ...
WebBACKGROUND: Irinotecan, a topoisomerase I inhibitor, is a cytotoxic chemotherapeutic agent used to treat multiple malignancies, including those of colorectal, pancreatic, cervical, esophageal, gastric, and lung origin.Dysarthria, a state of difficult or unclear articulation of speech, has been reported as a rare side effect of irinotecan through multiple case … WebJun 28, 2024 · Dysarthria, a state of difficult or unclear articulation of speech, has been reported as a rare side effect of irinotecan through multiple case reports and case series, … WebJul 1, 2008 · DISCUSSION. The mechanism by which irinotecan and its active metabolite SN-38 binds and inhibits anticholinesterase has been well described; 4, 5 however, the mechanism by which CNS toxicity occurs after irinotecan infusion is unclear. We are aware of four cases of irinotecaninduced dysarthria reported in the literature, 9 – 12 but to the … diablo 2 the smith location